NASDAQ: VIR

Brii Biosciences Ltd (HKG: 2137) has announced that two of its hepatitis B virus (HBV) drug candidates, BRII-835 (elebsiran) and BRII-877 (tobevibart), have been granted breakthrough therapy designations (BTDs) by China’s National Medical Products Administration (NMPA). BRII-877 (tobevibart) is a hepatitis B virus-specific broad-spectrum neutralizing monoclonal antibody (mAb) designed to…